• Cellectar BioSciences posted a net loss of about $5.7 million for three months ended March 31, 2026, using about $4.8 million in cash for operations.
• Research and development expense fell 12% to about $3.01 million, reflecting lower clinical project costs following completion of enrollment in Waldenstrom macroglobulinemia patients.
• General and administrative expense slipped 6% to about $2.79 million, while other income turned positive to about $140,000 on warrant-valuation changes.
• Cash balance was about $8.3 million at quarter-end, with available liquidity cited at about $37 million beyond the financial statement issuance date; absent added liquidity, funding under normal course may not extend beyond second quarter of 2027.
• Reported 12-month follow-up from CLOVER WaM Phase 2b showed 83.6% overall response rate and 61.8% major response rate, while a May 5 financing targeted about $35 million upfront with up to $105 million in milestone-based securities to support initiation of a Phase 3 confirmatory study in WM.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-060678), on May 14, 2026, and is solely responsible for the information contained therein.